MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Danaher Corp

Gesloten

SectorGezondheidszorg

205.16 2.59

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

199.35

Max

205.3

Belangrijke statistieken

By Trading Economics

Inkomsten

268M

1.1B

Verkoop

738M

6.5B

K/W

Sectorgemiddelde

38.752

63.778

EPS

2.14

Dividendrendement

0.62

Winstmarge

16.611

Werknemers

61,000

EBITDA

-230M

1.4B

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+28.05% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.62%

2.39%

Volgende Winsten

22 apr 2025

Volgende dividenddatum

25 apr 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-16B

147B

Vorige openingsprijs

202.57

Vorige sluitingsprijs

205.16

Nieuwssentiment

By Acuity

33%

67%

106 / 386 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

Danaher Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

5 feb 2025, 12:54 UTC

Winsten

Johnson Controls Names Weidemanis CEO, Logs 1Q Income Growth

29 jan 2025, 11:44 UTC

Winsten

Danaher 4Q Revenue Rises on Gains in Life Sciences, Biotech

22 okt 2024, 10:35 UTC

Winsten

Danaher 3Q EPS, Sales Top Views on Strong Cepheid Test Demand

23 jul 2024, 10:55 UTC

Winsten

Danaher Expects 3Q Core Sales Drop, Backs 2024 Guidance

29 jan 2025, 15:25 UTC

Marktinformatie
Winsten

Danaher's 2025 Sales Guidance Disappoints -- Market Talk

29 jan 2025, 13:56 UTC

Top Nieuws
Winsten

Danaher Had an Unusual Quarter. The Stock Is Down. -- Barrons.com

29 jan 2025, 11:08 UTC

Winsten

Danaher Sees 2025 Bioprocessing Core Revenue Growth 6%-7% >DHR

29 jan 2025, 11:07 UTC

Winsten

Danaher Sees 2025 Adjusted Operating Profit Margin About 28.5% >DHR

29 jan 2025, 11:07 UTC

Winsten

Danaher: Expect to Return to Growth, Build Back to Normal Market Conditions in 2025 >DHR

29 jan 2025, 11:02 UTC

Winsten

Danaher Sees 2025 Adjusted Core Revenue Up About 3% >DHR

29 jan 2025, 11:01 UTC

Winsten

Danaher Sees 1Q Adjusted Core Revenue Down Low-Single Digits >DHR

29 jan 2025, 11:01 UTC

Winsten

Danaher 4Q Operating Cash Flow $2B, Free Cash Flow $1.5B >DHR

29 jan 2025, 11:00 UTC

Winsten

Danaher 4Q Adjusted Core Revenue Rose 1% >DHR

29 jan 2025, 11:00 UTC

Winsten

Danaher 4Q Cont Ops EPS $1.49 >DHR

29 jan 2025, 11:00 UTC

Winsten

Danaher 4Q Net $1.09B >DHR

29 jan 2025, 11:00 UTC

Winsten

Danaher 4Q EPS $1.49 >DHR

29 jan 2025, 11:00 UTC

Winsten

Danaher 4Q Adj EPS $2.14 >DHR

29 jan 2025, 11:00 UTC

Winsten

Danaher 4Q Sales $6.5B >DHR

22 okt 2024, 10:02 UTC

Winsten

Danaher 3Q Adjusted Core Revenue Rose 0.5% >DHR

22 okt 2024, 10:02 UTC

Winsten

Danaher Still Sees 2024 Adjusted Core Revenue Down Low-Single Digits >DHR

22 okt 2024, 10:01 UTC

Winsten

Danaher Sees 4Q Adjusted Core Revenue Down Low-Single Digits >DHR

22 okt 2024, 10:00 UTC

Winsten

Danaher 3Q Operating Cash Flow $1.5B, Adjusted Free Cash Flow $1.2B >DHR

22 okt 2024, 10:00 UTC

Winsten

Danaher 3Q Sales $5.8B >DHR

22 okt 2024, 10:00 UTC

Winsten

Danaher 3Q EPS $1.12 >DHR

22 okt 2024, 10:00 UTC

Winsten

Danaher 3Q Adj EPS $1.71 >DHR

22 okt 2024, 10:00 UTC

Winsten

Danaher 3Q Net $818M >DHR

22 okt 2024, 10:00 UTC

Winsten

Danaher 3Q Cont Ops EPS $1.12 >DHR

23 jul 2024, 12:39 UTC

Top Nieuws
Winsten

Danaher Stock Surges. More Than Earnings Are Driving It Higher. -- Barrons.com

23 jul 2024, 10:05 UTC

Winsten

Danaher 2Q Adjusted Core Revenue Fell 3.5% >DHR

23 jul 2024, 10:05 UTC

Winsten

Danaher Sees 2024 Adjusted Core Revenue Down Low-Single Digits >DHR

Peer Vergelijking

Prijswijziging

Danaher Corp Prognose

Koersdoel

By TipRanks

28.05% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 262.71 USD  28.05%

Hoogste 300 USD

Laagste 240 USD

Gebaseerd op 17 Wall Street-analisten die 12-maands prijsdoelen bieden voor Danaher Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

17 ratings

13

Buy

4

Hold

0

Sell

Technische score

By Trading Central

199.78 / 210.26Steun & Weerstand

Korte Termijn

Strong Bearish Evidence

Gemiddeld Termijn

Weak Bearish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

106 / 386 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Danaher Corp

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.